Clinical Trial Update: A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 study of the investigational drug INCB050465 in relapsed or refractory Mantle Cell Lymphoma (with or without prior BTK inhibitor) has completed and it…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• INCB050465

Snippet

Sponsor: Incyte Corporation | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10